Section Arrow
BIOA.NASDAQ
- BioAge Labs Inc.
Quotes are at least 15-min delayed:2025/02/23 00:46 EST
Last
 4.5
+0.1 (+2.27%)
Day High 
4.54 
Prev. Close
4.4 
1-M High
5.45 
Volume 
70.45K 
Bid
4.32
Ask
4.54
Day Low
4.41 
Open
4.48 
1-M Low
4.19 
Market Cap 
157.73M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 4.45 
20-SMA 4.71 
50-SMA 5.25 
52-W High 26.62 
52-W Low 3.85 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.07/--
Enterprise Value
165.94M
Balance Sheet
Book Value Per Share
8.75
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
UPCUniverse Pharmaceuticals Inc0.2003+0.0578+40.56%-- 
TLRYTilray Brands0.9452+0.0775+8.93%-- 
CGCCanopy Growth Corp1.615+0.005+0.31%-- 
TXMDTherapeuticsMD1.291+0.281+27.82%0.39PE
TEVATeva Pharmaceutical Industries Limited16.74-0.26-1.53%-- 
Quotes are at least 15-min delayed:2025/02/23 00:46 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.